CIBMTR.org Forms Instruction Manual - 1

Lymphoma Response Criteria

Complete Remission (CR)

Complete disappearance of all known disease. For typically PET-avid lymphoma, a post-treatment residual mass of any size is permitted as long as it is PET negative. For variably, PET-avid lymphoma, all lymph nodes and nodal masses must have regressed as measured by CT to < 1.5 cm (for nodes > 1.5 cm before therapy) or < 1 cm (for nodes 1.1 cm to 1.5 cm before therapy)

Spleen/Liver

Not palpable; nodules disappeared

Bone Marrow

Infiltrate cleared on repeat biopsy. If indeterminate by morphology, immunohistochemistry should be negative

Partial Remission (PR)

≥ 50% reductions in the greatest diameter of up to six of the largest dominant nodes or nodal masses and no new sites. For typically PET-avid lymphoma, post-treatment PET should be positive in at least one site. For variably-PET avid lymphoma, use CT criteria

Spleen/Liver

 \geq 50% reduction in SPD of nodules; for single nodule, \geq 50% reduction in greatest transverse diameter. No increase in size of liver or spleen.

Bone Marrow

Irrelevant if positive prior to therapy. Cell type should be specified.

Stable Disease

Failure to attain CR, PR, or PD

Progressive Disease

Any new lesion and/or > 50% increase in the least diameter of previously involved sites

Spleen/Liver

> 50% increase from nadir of any previous lesions

CIBMTR.org Forms Instruction Manual - 1

Bone Marrow

New or recurrent involvement

Not Tested / Unknown

The results from the line of therapy are unknown

Not Assessed

No evaluation was performed for the line of therapy prior to the initiation of a new line of therapy or the start of the preparative regimen

Adapted from: Cheson, B. D., S. Stroobants, E. Zucca, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, R. I. Fisher, A. Hagenbeek, V. Diehl, T. A. Lister, R. T. Hoppe, M. Dreyling, K. Tobinai, J. M. Vose, J. M. Connors, M. Federico, and S. T. Rosen. "Revised Response Criteria For Malignant Lymphoma." *Journal of clinical oncology25.5* (2007): 579-586. Print.